Singapore HSA Integration: Implications for Medical Devices

Singapore is bringing more health regulatory functions under the Health Sciences Authority (HSA) and coordinating selected regulatory and health technology assessment (HTA) reviews. At the Health Regulatory Conference on 12 October 2026, the Ministry of Health (MOH) and HSA outlined changes intended to help useful innovations reach patients sooner. For medical device manufacturers, the immediate planning questions concern regulatory coordination and the precise scope of each initiative.

Integrated oversight for medical innovations

In its official keynote, HSA said MOH's regulatory functions and manpower would transition to HSA on 1 November 2026. Administrative and operational functions supporting the healthcare Professional Boards and Councils are to follow by the end of 2027.

HSA highlighted AI-enabled diagnostic tools as an example of overlapping responsibilities: product evaluation, the setting in which a service is delivered, professional use of the output, and health information governance. Bringing expertise together is intended to make these questions easier to navigate. HSA explicitly described its illustrative AI-device scenario as fictional, rather than an announcement of a specific platform or device approval.

The HTA Priority Track has a defined product scope

MOH announced an ACE–HSA Priority Track from November 2026, allowing coordinated regulatory and HTA evaluations for selected products.

However, the Agency for Care Effectiveness's implementation information states that the track currently covers therapeutic drugs and cell, tissue and gene therapy products (CTGTPs). Medical device manufacturers should therefore avoid assuming that their devices qualify.

ACE describes a target of six to nine months between regulatory approval and the first HTA decision for products using its Company-Led Submission process under the Priority Track, subject to timely provision of complete information. This is not a medical device registration timeline. Regulatory and HTA decisions remain independent, existing assessment standards remain in place, and participation does not guarantee approval or funding.

Pure Global's view: plan around the device and its deployment

For manufacturers preparing Singapore market entry, these announcements support a practical review of where a product's intended use intersects with its care setting, professional users and patient-data flows. AI-enabled device teams can use early regulatory engagement to clarify those connections.

Continue planning against the requirements applicable to the actual device and proposed service. Treat faster review or future HTA eligibility as conditional until official device-specific criteria support it. Our Singapore medical device regulatory guide provides a starting point for assessing the product-registration route.